LOP 628

Drug Profile

LOP 628

Alternative Names: Anti-c-kit humanised IgG1/κ antibody-maitansine conjugate - Novartis; Anti-c-kit humanised IgG1/κ antibody-maytansine conjugate - Novartis; Anti-proto-oncogene protein c-kit IgG1/kappa antibody-maitansine conjugate - Novartis; Anti-proto-oncogene protein c-kit IgG1/kappa antibody-maytansine conjugate - Novartis

Latest Information Update: 05 Oct 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Novartis Pharmaceuticals Corporation
  • Class Antineoplastics; Drug conjugates; Immunoconjugates; Maytansinoids
  • Mechanism of Action Apoptosis stimulants; Mitosis inhibitors; Tubulin inhibitors; Tubulin polymerisation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Suspended Acute myeloid leukaemia; Solid tumours

Most Recent Events

  • 01 Mar 2015 Novartis suspends phase I trial in Solid tumours and Acute myeloid leukaemia in the USA, Australia and Netherlands (NCT02221505)
  • 01 Dec 2014 Phase-I clinical trials in Acute myeloid leukaemia in USA, Australia and the Netherlands (IV)
  • 01 Dec 2014 Phase-I clinical trials in Solid tumours in USA, Australia and the Netherlands (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top